LONDON, (January 25, 2005) — Inpharmatica Ltd, a drug discovery company, has announced a series of agreements with Pfizer. This provides Pfizer with access to four core components of Inpharmatica’s PharmaCarta™ gene to candidate technology platform. These components are provided to Pfizer in addition to their Biopendium™ subscription, which now moves into its sixth year. The financial terms of the agreement were not disclosed.
Inpharmatica will use its proprietary technology for target druggability assessment; Pfizer will gain access to StARLITe™, a database containing 20 years of curated medicinal chemistry information on compound structure and bioactivity linked to targets; to DrugStore™, a curated database of all known drugs, linked with their targets; and to Admensa, Inpharmatica’s proprietary technology for assessing the ADME (absorption, distribution, metabolism, and excretion) characteristics of therapeutic compounds and compound libraries.
PharmaCarta™ is Inpharmatica’s gene to candidate platform, which bridges the gap between biology and chemistry. PharmaCarta facilitates target selection through druggability assessment linked to electronic identification of potential compounds biased for good drug-like characteristics.
Commenting on the announcement, John Lisle, Chief Executive Officer of Inpharmatica, said:”This is a very exciting partnership for Inpharmatica. Pfizer has been a long-standing customer of Inpharmatica by subscribing to Biopendium™, and we are very pleased that this relationship has now grown to encompass additional components of Inpharmatica’s PharmaCarta platform. In particular we are delighted to be adding value to Pfizer’s already world class expertise in assessing target druggability through their use of our technology. We look forward to this new partnership with Pfizer.”